BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Cowen Starts Regulus Therapeutics (RGLS) at Outperform
October 31, 2012 8:27 AM EDTCowen initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday, with a 52 week range of $4.02-$5.48.... More



